Is plasma p-tau217 as useful as CSF for Alzheimer PET positivity?
In 114 Geneva memory-clinic patients, plasma p-tau217 identified amyloid/tau PET positivity (mean AUC 0.96) better than p-tau181/231 and similarly to CSF p-tau217 (AUC 0.95).
Source
Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort
Study at a glance
- Design
- Cross-sectional — Head-to-head diagnostic-accuracy study of plasma and CSF p-tau217 vs p-tau181 and p-tau231 against amyloid- and tau-PET in a Geneva memory-clinic cohort.
- N
- N=114 · 114 participants (CU 33, MCI 67, dementia 14); CSF subset n=36.
- Population
- Memory-clinic patients at Geneva University Hospitals spanning cognitively unimpaired, MCI, and dementia.
- Outcome
- Correlation with A/T-PET, group effect sizes, and ROC AUC for amyloid- and tau-PET positivity.
Structured fields used in claim comparison tables when every cited study has a complete layer.
What they did
Correlated plasma and CSF p-tau217/181/231 with continuous amyloid- and tau-PET, compared effect sizes across diagnosis and A/T groups, and ran ROC analyses for PET positivity.
What they found
Plasma/CSF p-tau217 correlated more strongly with A- and T-PET (r 0.64–0.83) than p-tau181 or p-tau231. Plasma p-tau217 had larger group δ (0.55–0.96) and mean AUC 0.96 vs 0.76 (181) and 0.79 (231). CSF p-tau217 AUC 0.95 did not significantly beat CSF 181/231 (0.88/0.89). Authors conclude plasma p-tau217 performed like CSF and could reduce invasive testing.
The limits
What it doesn't show
CSF n=36 is too small for a firm plasma-vs-CSF contest, and cohort-specific cut-offs plus a single memory clinic limit transportability.
Key terms
- p-tau217
- Tau phosphorylated at threonine 217; best plasma marker here for A/T-PET.
- p-tau181 / p-tau231
- Comparator phospho-tau epitopes with lower plasma AUCs in this cohort.
- A-PET / T-PET
- Amyloid and tau positron-emission tomography used as imaging standards.
- AUC
- Area under the ROC curve for PET positivity; plasma p-tau217 mean AUC 0.96.
- MCI
- Mild cognitive impairment; 67 of 114 participants.
- Simoa / MSD
- Homebrew Simoa (181/231) and Lilly MSD immunoassay (217) platforms.
Flashcards
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
Memory-clinic n was:
Common questions
How many participants?
114 (33 cognitively unimpaired, 67 MCI, 14 dementia).
Plasma p-tau217 mean AUC vs PET?
0.96, versus 0.76 (181) and 0.79 (231).
Did CSF p-tau217 beat other CSF epitopes?
Not significantly (AUC 0.95 vs 0.88 and 0.89).
Main CSF limitation?
Only 36 people had CSF, limiting plasma–CSF comparison.
More on Diagnostic accuracy